blockbusters news from FierceBiotech
News
Daiichi snares Germany's U3 in $235M acquisition
Daiichi Sankyo is buying Germany's U3 Pharma for $235 million in cash. The Japanese pharma company gains a developer that's been Read more...
Deloitte sees 'fundamental shift' in drug dev. strategies
Deloitte sees a major shakeup going on in clinical research strategies at the large pharma companies. Instead of focusing on the development of a small portfolio of Read more...
ALSO NOTED: Apoptos gains $28M Series A; Commonwealth Biotechnologies venture to recruit 1,000 chemists in China;and much more.
> Apoptos will get a two-tranche Series A of $28 million from a group of investors that includes Venrock, ARCH Venture Partners, OrbiMed Advisors, and Advanced Technology Ventures. The developer Read more...
Merck shares hammered after FDA rejects Cordaptive
Shares of Merck were sliding again this morning on the news that the FDA has turned thumbs down on MK-0524A, its new cholesterol therapy. The stock dropped eight percent after regulators announced Read more...
Investors fret over Lilly's pipeline, Prasugel data
Barron's concludes that Eli Lilly's anti-clotting drug Prasrugel will probably make it to the market, but recent safety data is likely to prevent it from becoming the kind of blockbuster the drug Read more...
Anti-TNF blockbuster garners positive Phase III data
Schering-Plough, Johnson & Johnson and Medarex unveiled positive new data from two late-stage studies of golimumab, an experimental Read more...
MAbs are hottest segment of biotech industry
Looking for the hottest segment of the biotech industry? Then take a look at monoclonal antibodies (mAbs). A new Datamonitor report projects 14 percent annual growth in the market for the antibody Read more...
Pfizer tops the charts in global R&D spending
It hasn't had a lot to show for it so far, but Pfizer became the world's number one spender on research and development last year, grabbing the top spot from Ford. The list, assembled by the Read more...
Deals and more deals
The surge in values for biotech buyouts this past year has recalibrated quite a few business plans. Just yesterday GlaxoSmithKline willingly put down twice the value of Praecis stock to lock up the buyout. That was just a small deal when compared to the recent buyout of Domantis. These days, when a big …
Read more...Glaxo forges $2.1B deal for HuMax-CD20
Denmark's Genmab will gain up to $2.1 billion in a licensing deal with GlaxoSmithKline for the HuMax-CD20 antibody for leukemia, far outstripping the numbers predicted by analysts. Genmab will get $102 million up front, a 10 percent equity investment worth $357 million and up to $1.6 billion in milestone payments. The therapy is in a late-stage trial for chronic lymphocytic leukemia and non-Hodkin's lymphoma and in mid-stage trials for rheumatoid arthritis and new cases of lymphocytic …
Read more...Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends